Form 4: Lyell Immunopharma CMO David Shook Receives Significant Equity Awards

Lyell Immunopharma's Chief Medical Officer, David Shook, was granted 21,900 restricted stock units and options to purchase 43,750 shares of common stock, effective June 9, 2025.

Summary

• David Shook, the Chief Medical Officer of Lyell Immunopharma, Inc. (LYEL), reported the acquisition of equity awards on June 9, 2025.
• The awards include 21,900 Restricted Stock Units (RSUs) granted at a price of $0.
• The RSUs will vest 25% on June 9, 2026, with an additional 1/16th of the total shares vesting per quarter thereafter, contingent on continued service.
• Additionally, Mr. Shook was granted options to purchase 43,750 shares of common stock at an exercise price of $12.47.
• These options will vest 25% on June 9, 2026, with the remaining shares vesting in equal monthly installments over the subsequent thirty-six months, also subject to continued service.
• Following these transactions, Mr. Shook beneficially owns 21,900 shares of common stock and options for 43,750 shares.

Sentiment

Score: 8

Explanation: The grant of significant equity awards to a key executive is generally a positive signal, as it aligns management's long-term interests with those of shareholders and serves as a retention mechanism. It reflects a commitment to the company's future.

Positives

• The grant of significant equity awards to the Chief Medical Officer aligns management's long-term interests with those of shareholders, incentivizing performance.
• Equity grants are a standard practice for executive retention and motivation in the biotechnology sector, indicating a commitment to the executive's role and the company's future.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the reporting person providing continuous service through the specified vesting dates, meaning the awards could be forfeited if employment ceases.

Future Outlook

The multi-year vesting schedules for both the Restricted Stock Units and stock options, extending through June 2026 and beyond, indicate a long-term incentive structure designed to retain the Chief Medical Officer and align his performance with the company's future success and shareholder value creation.

Management Comments

• The equity grants are part of the Issuer's 2021 Equity Incentive Plan, designed to incentivize the reporting person and align their interests with the company's long-term performance.

Industry Context

Equity grants, including Restricted Stock Units and stock options with multi-year vesting schedules, are a standard and widely adopted practice in the biotechnology and pharmaceutical industries. These compensation structures are crucial for attracting, retaining, and motivating key executives, particularly in companies with long development cycles and significant R&D investments, as they align executive compensation with the achievement of long-term strategic goals and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options with performance-based or time-based vesting is a common compensation strategy for executives across the biotech and pharmaceutical sectors, similar to practices observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their senior leadership.
• The multi-year vesting schedule (25% after one year, then quarterly/monthly over subsequent years) is typical for executive equity awards, designed to ensure long-term retention and alignment, mirroring structures seen in comparable biopharmaceutical firms aiming to secure talent for extended periods of drug development and commercialization.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's financial interests directly with the long-term performance of the company, potentially leading to enhanced shareholder value.
• Employees: May signal stability and confidence in the company's future from senior leadership, potentially boosting morale and retention.

Next Steps

• The Chief Medical Officer must continue providing service to Lyell Immunopharma to meet the vesting conditions for both the Restricted Stock Units and stock options.
• Future SEC Form 4 filings will report subsequent vesting events, exercises, or sales of these securities.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, LYEL, David Shook, Chief Medical Officer, CMO, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Executive Compensation, Insider Transaction, SEC Form 4